The health risks of e-cigarettes have come into focus after the deaths of several “vapers” due to lung injury in the USA recently. These health risks were discussed in press reports on eight young people who were poisoned in Bremerhaven in October 2019. Patients suffered from convulsive seizures, impaired consciousness and memory, and heart palpitations.
According to a preliminary assessment from the German Federal Institute for Risk Assessment (BfR), the prohibited use of synthetic cannabinoids in e-liquids can be assumed with high likelihood as reason for the observed symptoms. According to media reports, the patients admitted to have consumed cannabidiol (CBD). CBD is a weakly psychoactive cannabinoid. Already a year ago, the use of CBD liquids manipulated with psychoactive cannabinoids has been reported on from the USA. The users suffered from neurological symptoms as the youths in Bremerhaven.
Thus, both case series share similar symptoms - including the fact that no respiratory symptoms appeared - and the absence of fatal cases in contrast to earlier reports from the USA. The cases of poisoning in Bremerhaven can only be assessed to a limited extent by BfR due to the lack of sufficient available information. Further data, particularly regarding the products, additives, and devices used, are required for a toxicological risk assessment. At the moment, there are no hints that indicate the cause or enhancement of the symptoms of poisoning by e-cigarettes.
However, e-cigarettes in general, with nicotine or nicotine free, compromise health. Subject of the assessment
The BfR has issued a statement regarding possible health risks arising from the use of ecigarettes recently. The background are media reports1 dated 25 October 2019 in Bremen, covering poisoning of eight youths in Bremerhaven that was attributed to the use of ecigarettes. Although the symptoms in the Bremerhaven case series were clearly different from the severe respiratory illnesses in the USA, the cases were partially summarised. Poisoning was attributed to e-cigarettes as a new consumption habit - with no differentiation with regard to the e-liquids consumed. Results
With a very high likelihood, the poisoning cases in Bremerhaven are due to the use of synthetic cannabinoids in e-liquids. They clearly differ to the current cases of severe illness in the USA.
Already one-and-a-half years ago, there were cases reported from USA similar to the cases in Bremerhaven. The cases of illness or poisoning were attributed to manipulated cannabidiol liquids (CBD liquids) by the American authorities. The cases of poisoning in Bremerhaven are, based on current knowledge, due to other psychoactive synthetic cannabinoids. The liquids in question were acquired from a tobacconist in some cases. The BfR has no information regarding the origin of the liquids containing cannabinoids.
It is also possible that the e-liquids used in Bremerhaven were spiked with so-called incense or herbal blends. These are mixtures that may contain synthetic cannabinoids such as 5FADB, Cumyl-PeGaClone or 5F-Cumyl-P7AICA and that are misused for smoking. Synthetic cannabinoids could also have been mixed to the liquids in a different form, such as crystals or solids.
The assessment of the current cases in Germany is only possible to a limited extent due to the lack of available information. Further information, particularly regarding the products, additives, and devices used, is required for a toxicological risk assessment. The products that were consumed should be subjected to full chemical analysis and characterization. Furthermore, there is the question whether further illegal substances have been spread via CBD products.
At the moment, there are no hints that e-cigarettes as an application have triggered or enhanced the symptoms of poisoning. The current opinions of the BfR therefore remain valid. E-cigarettes in general, either with nicotine or nicotine free, compromise health. Risk assessment and discussion
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology